Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV000513599 | SCV000608826 | uncertain significance | not provided | 2017-06-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000631475 | SCV000752556 | uncertain significance | Osteogenesis imperfecta type I | 2025-01-23 | criteria provided, single submitter | clinical testing | This sequence change falls in intron 49 of the COL1A1 gene. It does not directly change the encoded amino acid sequence of the COL1A1 protein. It affects a nucleotide within the consensus splice site. This variant is present in population databases (rs778417218, gnomAD 0.01%). This variant has been observed in individual(s) with COL1A1-related conditions (PMID: 25963598). ClinVar contains an entry for this variant (Variation ID: 444409). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant is not likely to affect RNA splicing. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
ARUP Laboratories, |
RCV001001319 | SCV001158506 | uncertain significance | not specified | 2019-06-27 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV000513599 | SCV002541425 | uncertain significance | not provided | 2021-05-13 | criteria provided, single submitter | clinical testing | |
Genome Diagnostics Laboratory, |
RCV002279299 | SCV002565529 | uncertain significance | Ehlers-Danlos syndrome | 2021-05-17 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002376949 | SCV002624524 | uncertain significance | Cardiovascular phenotype | 2019-03-27 | criteria provided, single submitter | clinical testing | The c.4005+5G>A intronic variant results from a G to A substitution 5 nucleotides after coding exon 49 in the COL1A1 gene. This alteration has been reported in an osteogenesis imperfecta cohort (Schleit J et al. Hum. Mutat., 2015 Jul;36:728-39). This nucleotide position is well conserved in available vertebrate species. Using the BDGP and ESEfinder splice site prediction tools, this alteration is predicted to weaken the efficiency of the native splice donor site; however, direct evidence is unavailable. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV002496974 | SCV002777706 | uncertain significance | Osteogenesis imperfecta with normal sclerae, dominant form; Osteogenesis imperfecta, perinatal lethal; Osteogenesis imperfecta type III; Infantile cortical hyperostosis; Ehlers-Danlos syndrome, arthrochalasia type; Osteogenesis imperfecta type I; Osteoporosis; Combined osteogenesis imperfecta and Ehlers-Danlos syndrome 1 | 2022-02-23 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000513599 | SCV004235392 | uncertain significance | not provided | 2023-04-21 | criteria provided, single submitter | clinical testing |